Zevra Therapeutics (ZVRA) Gross Profit (2019 - 2026)

Zevra Therapeutics' Gross Profit history runs 7 years deep, the most recent figure standing at $34.3 million for Q1 2026.

• Quarterly Gross Profit rose 80.13% year-over-year to $34.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $105.3 million (up 229.89% YoY) and the FY2025 annual result came in at $90.0 million, up 455.65% from the prior year.
• Gross Profit was $34.3 million for Q1 2026 at Zevra Therapeutics, up from $32.6 million in the prior quarter.
• Across five years, Gross Profit topped out at $34.3 million in Q1 2026 and bottomed at -$8000.0 in Q1 2022.
• A 5-year average of $10.1 million and a median of $3.2 million in 2024 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2023 — Gross Profit soared 38237.5% — and 2024, when it slumped 89.39%.
• Zevra Therapeutics' Gross Profit stood at $1.9 million in 2022, then surged by 505.85% to $11.7 million in 2023, then dropped by 8.95% to $10.6 million in 2024, then jumped by 206.69% to $32.6 million in 2025, then climbed by 5.12% to $34.3 million in 2026.
• Business Quant data shows ZVRA's Gross Profit at $34.3 million in Q1 2026, $32.6 million in Q4 2025, and $24.8 million in Q3 2025.